{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T09:08:51Z","timestamp":1696324131891},"reference-count":12,"publisher":"Oxford University Press (OUP)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,5,15]]},"DOI":"10.2146\/ajhp120137","type":"journal-article","created":{"date-parts":[[2013,5,3]],"date-time":"2013-05-03T05:11:32Z","timestamp":1367557892000},"page":"874-876","source":"Crossref","is-referenced-by-count":7,"title":["Toxic epidermal necrolysis associated with rifaximin"],"prefix":"10.1093","volume":"70","author":[{"given":"Aneesh S.","family":"Patel","sequence":"first","affiliation":[{"name":"In Clinical Development, Allergan, Inc., Irvine, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa M.","family":"Supan","sequence":"additional","affiliation":[{"name":"Methodist Willowbrook Hospital, Houston, TX; at the time of writing, she was Clinical Pharmacy Specialist, Kennedy Health System, Washington Township Division, Turnersville, NJ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shereef N.","family":"Ali","sequence":"additional","affiliation":[{"name":"Kennedy Health System, Cherry Hill Division, Cherry Hill, NJ"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"2019041206023067000_b1-0700874","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1056\/NEJMoa0907893","article-title":"Rifaximin treatment in hepatic encephalopathy","volume":"362","author":"Bass","year":"2010","journal-title":"N Engl J Med"},{"key":"2019041206023067000_b2-0700874","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1056\/NEJM199708143370707","article-title":"Treatment of hepatic encephalopathy","volume":"337","author":"Riordan","year":"1997","journal-title":"N Engl J Med"},{"key":"2019041206023067000_b3-0700874","unstructured":"Food and Drug Administration. FDA approves new use of Xifaxan for patients with liver disease. www.fda.gov\/newsevents\/newsroom\/pressannouncements\/ucm206104.htm (accessed 2013 Feb 8)."},{"key":"2019041206023067000_b4-0700874","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1185\/03007999309111539","article-title":"Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy","volume":"13","author":"Bucci","year":"1993","journal-title":"Curr Med Res Opin"},{"key":"2019041206023067000_b5-0700874","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jinf.2004.05.019","article-title":"Rifaximin: a novel antimicrobial for enteric infections","volume":"50","author":"Huang","year":"2005","journal-title":"J Infect"},{"key":"2019041206023067000_b6-0700874","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2133.1956.tb12766.x","article-title":"Toxic epidermal necrolysis: an eruption resembling scalding of the skin","volume":"68","author":"Lyell","year":"1956","journal-title":"Br J Dermatol"},{"key":"2019041206023067000_b7-0700874","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1586\/eci.11.66","article-title":"The current understanding of Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"7","author":"Mockenhaupt","year":"2011","journal-title":"Expert Rev Clin Immunol"},{"key":"2019041206023067000_b8-0700874","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1056\/NEJM199512143332404","article-title":"Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis","volume":"333","author":"Roujeau","year":"1995","journal-title":"N Engl J Med"},{"key":"2019041206023067000_b9-0700874","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"2019041206023067000_b10-0700874","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0190-9622(87)80324-9","article-title":"Toxic epidermal necrolysis due to rifampicin","volume":"17","author":"Okano","year":"1987","journal-title":"J Am Acad Dermatol"},{"key":"2019041206023067000_b11-0700874","doi-asserted-by":"crossref","first-page":"629","DOI":"10.3109\/00365549009027111","article-title":"Lyell\u2019s syndrome associated with rifampicin therapy of tuberculosis in an AIDS patient","volume":"22","author":"Prazuck","year":"1990","journal-title":"Scand J Infect Dis"},{"key":"2019041206023067000_b12-0700874","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2332\/allergolint.55.9","article-title":"Toxic epidermal necrolysis and Stevens Johnson syndrome: our current understanding","volume":"55","author":"French","year":"2006","journal-title":"Allergol Int"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/70\/10\/874\/28363902\/ajhp0874.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,13]],"date-time":"2019-04-13T00:16:24Z","timestamp":1555114584000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/70\/10\/874\/5112241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,15]]},"references-count":12,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2013,5,15]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp120137","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2013,5,15]]},"published":{"date-parts":[[2013,5,15]]}}}